S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:BLPH

Bellerophon Therapeutics (BLPH) Stock Price, News & Analysis

$0.06
0.00 (0.00%)
(As of 03/28/2024 ET)
Today's Range
$0.06
$0.06
50-Day Range
$0.05
$0.07
52-Week Range
$0.03
$12.58
Volume
60 shs
Average Volume
32,450 shs
Market Capitalization
$694,847.45
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.00

Bellerophon Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
3,420.2% Upside
$2.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.86
Upright™ Environmental Score
News Sentiment
0.46mentions of Bellerophon Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.81 out of 5 stars

BLPH stock logo

About Bellerophon Therapeutics Stock (NASDAQ:BLPH)

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

BLPH Stock Price History

BLPH Stock News Headlines

[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
Bellerophon Therapeutics, Inc. (BLPH)
Bellerophon Therapeutics Inc (BLPH)
Bellerophon Therapeutics Inc BLPH
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
BLPH - Bellerophon Therapeutics, Inc.
The Latest Analyst Ratings for Bellerophon Therapeutics
See More Headlines
Receive BLPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellerophon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/14/2023
Today
3/28/2024
Next Earnings (Estimated)
3/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BLPH
Fax
N/A
Employees
18
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.00
High Stock Price Target
$2.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+3,420.2%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-19,830,000.00
Pretax Margin
-186.70%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.27 per share

Miscellaneous

Free Float
11,597,000
Market Cap
$694,847.45
Optionable
Optionable
Beta
0.67
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

BLPH Stock Analysis - Frequently Asked Questions

Should I buy or sell Bellerophon Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BLPH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLPH, but not buy additional shares or sell existing shares.
View BLPH analyst ratings
or view top-rated stocks.

What is Bellerophon Therapeutics' stock price target for 2024?

3 brokers have issued 1-year price objectives for Bellerophon Therapeutics' shares. Their BLPH share price targets range from $2.00 to $2.00. On average, they predict the company's stock price to reach $2.00 in the next year. This suggests a possible upside of 3,420.2% from the stock's current price.
View analysts price targets for BLPH
or view top-rated stocks among Wall Street analysts.

How have BLPH shares performed in 2024?

Bellerophon Therapeutics' stock was trading at $0.0370 on January 1st, 2024. Since then, BLPH stock has increased by 53.6% and is now trading at $0.0568.
View the best growth stocks for 2024 here
.

When is Bellerophon Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024.
View our BLPH earnings forecast
.

How were Bellerophon Therapeutics' earnings last quarter?

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) released its quarterly earnings results on Monday, August, 14th. The biotechnology company reported ($0.42) earnings per share for the quarter.

When did Bellerophon Therapeutics' stock split?

Shares of Bellerophon Therapeutics reverse split before market open on Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 7th 2020. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Bellerophon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Corbus Pharmaceuticals (CRBP), Novavax (NVAX), Pfizer (PFE), Verastem (VSTM), Gilead Sciences (GILD), OPKO Health (OPK), SCYNEXIS (SCYX) and Dynavax Technologies (DVAX).

When did Bellerophon Therapeutics IPO?

Bellerophon Therapeutics (BLPH) raised $60 million in an initial public offering on Friday, February 13th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Leerink Partners and Cowen and Company acted as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

Who are Bellerophon Therapeutics' major shareholders?

Bellerophon Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bobae Kim, Life Science Opportu Puissance and Puissance Capital Management L.
View institutional ownership trends
.

How do I buy shares of Bellerophon Therapeutics?

Shares of BLPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BLPH) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners